We are live on ! Find out more
AZN icon

AstraZeneca

544 hedge funds and large institutions have $17.3B invested in AstraZeneca in 2018 Q3 according to their latest regulatory filings, with 65 funds opening new positions, 151 increasing their positions, 197 reducing their positions, and 47 closing their positions.

New
Increased
Maintained
Reduced
Closed

207% more call options, than puts

Call options by funds: $225M | Put options by funds: $73.5M

38% more first-time investments, than exits

New positions opened: 65 | Existing positions closed: 47

23% more capital invested

Capital invested by funds: $14B → $17.3B (+$3.3B)

3% more funds holding

Funds holding: 530544 (+14)

1.19% more ownership

Funds ownership: 16.09%17.28% (+1.2%)

23% less repeat investments, than reductions

Existing positions increased: 151 | Existing positions reduced: 197

40% less funds holding in top 10

Funds holding in top 10: 53 (-2)

Holders
544
Holders Change
+14
Holders Change %
+2.64%
% of All Funds
12.44%
Holding in Top 10
3
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-40%
% of All Funds
0.07%
New
65
Increased
151
Reduced
197
Closed
47
Calls
$225M
Puts
$73.5M
Net Calls
+$152M
Net Calls Change
+$45M
Name Holding Trade Value Shares
Change
Change in
Stake
BOH
126
Bank of Hawaii
Hawaii
$3.67M -$207K -2,740 -6%
GCAC
127
Guardian Capital Advisors (Canada)
Ontario, Canada
$3.58M -$27.2K -360 -0.8%
Calamos Advisors
128
Calamos Advisors
Illinois
$3.53M +$3.38M +44,650 New
BBA
129
BLB&B Advisors
Pennsylvania
$3.53M +$733K +9,688 +28%
SFI
130
Susquehanna Fundamental Investments
Pennsylvania
$3.44M
CCP
131
Corient Capital Partners
California
$3.44M
BFM
132
Boston Financial Management
Massachusetts
$3.42M -$93.8K -1,240 -3%
CIBC World Market
133
CIBC World Market
Ontario, Canada
$3.41M +$30.5K +403 +0.9%
FAM
134
Fred Alger Management
New York
$3.3M +$983K +13,000 +45%
AIA
135
Avalon Investment & Advisory
Texas
$3.3M +$994K +13,138 +46%
Susquehanna International Group
136
Susquehanna International Group
Pennsylvania
$3.21M -$1.81M -23,931 -37%
ACI
137
AMP Capital Investors
Australia
$3.11M +$2.25M +29,786 +319%
CA
138
Continental Advisors
Utah
$3.1M -$756K -10,000 -20%
AAM
139
Advisors Asset Management
Colorado
$3.02M -$293K -3,872 -9%
PNC
140
Park National Corp
Ohio
$2.98M +$2.85M +37,685 New
CPA
141
Cowen Prime Advisors
New York
$2.82M -$280K -3,700 -9%
JMPWA
142
JP Morgan Private Wealth Advisors
California
$2.8M -$65K -859 -2%
PRS
143
Pinkerton Retirement Specialists
Idaho
$2.62M -$6.28K -83 -0.3%
VIA
144
Vident Investment Advisory
Georgia
$2.58M -$143K -1,891 -5%
US Bancorp
145
US Bancorp
Minnesota
$2.55M -$605 -8 -0%
WAM
146
World Asset Management
Michigan
$2.55M -$434K -5,736 -15%
AG
147
Advisor Group
Arizona
$2.48M +$173K +2,285 +8%
TSS
148
Two Sigma Securities
New York
$2.42M +$1.53M +20,225 +195%
CGH
149
Crossmark Global Holdings
Texas
$2.42M +$922K +12,184 +66%
ACS
150
Archford Capital Strategies
Illinois
$2.37M -$281K -3,709 -11%

AZN Hedge Fund Activity: Q3 2018 in Review

544 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in AstraZeneca (AZN) for Q3 2018, worth a combined $17.3B — up 23% from $14B a quarter earlier.

Buyers outnumbered sellers: 65 funds opened new AZN positions and 47 closed out — a net gain of 18 holders — while 151 added to existing stakes and 197 trimmed.

The largest buyer was Jennison Associates, adding an estimated $774M. The largest seller was Bank of America, cutting an estimated $123M.

  • 544 institutional investors held AstraZeneca (AZN) as of Q3 2018, up from 530 in Q2 2018.
  • Funds reported $17.3B of AstraZeneca stock for Q3 2018, up 23% quarter-over-quarter.
  • 65 funds opened new AstraZeneca positions in Q3 2018 and 47 closed out, a net change of +18 holders.
  • The largest AstraZeneca buyer in Q3 2018 was Jennison Associates, an estimated $774M added.
  • The largest AstraZeneca seller in Q3 2018 was Bank of America, an estimated $123M sold.

Based on aggregated 13F filings for Q3 2018.